Compare HFBL & CSBR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | HFBL | CSBR |
|---|---|---|
| Founded | 1924 | 1985 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Savings Institutions | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 77.3M | 81.0M |
| IPO Year | 2010 | 2015 |
| Metric | HFBL | CSBR |
|---|---|---|
| Price | $25.99 | $5.29 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 2.0K | ★ 6.4K |
| Earning Date | 05-12-2026 | 03-12-2026 |
| Dividend Yield | ★ 2.83% | N/A |
| EPS Growth | ★ 7.69 | N/A |
| EPS | ★ 1.55 | N/A |
| Revenue | $1,303,000.00 | ★ $2,900,000.00 |
| Revenue This Year | N/A | $4.84 |
| Revenue Next Year | N/A | $11.51 |
| P/E Ratio | $16.15 | ★ N/A |
| Revenue Growth | ★ 17.49 | N/A |
| 52 Week Low | $13.45 | $4.83 |
| 52 Week High | $28.00 | $8.74 |
| Indicator | HFBL | CSBR |
|---|---|---|
| Relative Strength Index (RSI) | 59.03 | 56.18 |
| Support Level | $21.08 | $4.83 |
| Resistance Level | $28.00 | $6.31 |
| Average True Range (ATR) | 0.42 | 0.20 |
| MACD | -0.06 | 0.06 |
| Stochastic Oscillator | 37.54 | 83.82 |
Home Federal Bancorp Inc of louisiana operates as a bank holding company. It is a federally chartered stock savings bank, which provides financial services to individuals, corporate entities, and other organizations. Its core activities consist of attracting deposits from the general public and using those funds to originate loans to the residential, commercial and multi-family segments. The company also invests securities held-to-maturity and securities available for sale.
Champions Oncology Inc is a USA based company which is engaged in the development and sale of state of the art technology solutions and products to personalize the development and use of oncology drugs. The company operates through one segment namely Personalized Oncology Solutions (POS) and Translational Oncology Solutions (TOS). Its POS business assists physicians in developing personalized treatment options for their cancer patients through tumor-specific data obtained from drug panels and related personalized oncology services. The TOS business assists pharmaceutical and biotechnology companies with their drug development process and offers studies or license tumors for use in studies. The company's revenue is majorly derived from research services.